Newsletter Subscription

Enter Name and Email

01 July 2010 - Just published: Review of 5-HT1A action of antipsychotics

Several novel antipsychotics exhibit agonism at serotonin 5-HT1A receptors. This is associated with improved cognition, reduced mood deficits and lessened extrapyramidal symptoms (EPS) liability. But how much activation of 5-HT1A receptors is necessary and desirable? This new review discusses these issues and proposes an interpretative framework for assessing antipsychotic candidates exhibiting combined 5-HT1A and D2 receptor properties.
For more information, Contact.

 

The importance of 5-HT1A receptor agonism in antipsychotic drug action: Rationale and perspectives.
Newman-Tancredi A.
Curr Opin Investig Drugs. 2010 Jul;11(7):802-12.